Charles Schwab Investment Management Inc Mirati Therapeutics, Inc. Transaction History

Charles Schwab Investment Management Inc

$515 Billion
Q3 2024

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 06, 2024	BUY	$41.99 - $62.38 $923,192 - $1.37 Million	21,986 Added 6.4%	365,428 $21.5 Million
Q3 2023 Nov 08, 2023	SELL	$27.8 - $45.35 $2.57 Million - $4.2 Million	-92,606 Reduced 21.24%	343,442 $15 Million
Q2 2023 Aug 09, 2023	BUY	$36.13 - $49.49 $200,666 - $274,867	5,554 Added 1.29%	436,048 $15.8 Million
Q1 2023 May 11, 2023	SELL	$36.54 - $54.26 $53,677 - $79,707	-1,469 Reduced 0.34%	430,494 $16 Million
Q4 2022 Feb 13, 2023	BUY	$41.27 - $98.62 $1.15 Million - $2.74 Million	27,789 Added 6.88%	431,963 $19.6 Million
Q3 2022 Nov 14, 2022	BUY	$59.5 - $86.7 $670,803 - $977,455	11,274 Added 2.87%	404,174 $28.2 Million
Q2 2022 Aug 15, 2022	SELL	$39.16 - $88.71 $2,271 - $5,145	-58 Reduced 0.01%	392,900 $26.4 Million
Q1 2022 May 13, 2022	BUY	$75.82 - $150.97 $798,308 - $1.59 Million	10,529 Added 2.75%	392,958 $32.3 Million
Q4 2021 Feb 11, 2022	BUY	$132.01 - $190.29 $4.67 Million - $6.74 Million	35,404 Added 10.2%	382,429 $56.1 Million
Q3 2021 Nov 16, 2021	BUY	$132.13 - $177.45 $628,542 - $844,129	4,757 Added 1.39%	347,025 $61.4 Million
Q2 2021 Aug 16, 2021	SELL	$144.0 - $179.73 $10.7 Million - $13.4 Million	-74,530 Reduced 17.88%	342,268 $55.3 Million
Q1 2021 May 17, 2021	BUY	$158.92 - $221.61 $1.77 Million - $2.47 Million	11,135 Added 2.74%	416,798 $71.4 Million
Q4 2020 Feb 16, 2021	BUY	$162.05 - $240.27 $9.29 Million - $13.8 Million	57,335 Added 16.46%	405,663 $89.1 Million
Q3 2020 Nov 13, 2020	BUY	$113.26 - $167.27 $9.86 Million - $14.6 Million	87,073 Added 33.33%	348,328 $57.8 Million
Q2 2020 Aug 14, 2020	BUY	$72.01 - $120.39 $2.38 Million - $3.99 Million	33,119 Added 14.52%	261,255 $29.8 Million
Q1 2020 May 15, 2020	BUY	$69.78 - $116.21 $2.31 Million - $3.84 Million	33,085 Added 16.96%	228,136 $17.5 Million
Q4 2019 Feb 07, 2020	BUY	$70.76 - $128.86 $373,612 - $680,380	5,280 Added 2.78%	195,051 $25.1 Million
Q3 2019 Nov 08, 2019	BUY	$77.91 - $109.6 $737,418 - $1.04 Million	9,465 Added 5.25%	189,771 $14.8 Million
Q2 2019 Aug 09, 2019	BUY	$59.49 - $104.71 $653,914 - $1.15 Million	10,992 Added 6.49%	180,306 $18.6 Million
Q1 2019 May 14, 2019	BUY	$43.65 - $78.95 $697,876 - $1.26 Million	15,988 Added 10.43%	169,314 $12.4 Million
Q4 2018 Feb 14, 2019	SELL	$32.0 - $47.43 $25,408 - $37,659	-794 Reduced 0.52%	153,326 $6.51 Million
Q3 2018 Nov 13, 2018	BUY	$47.1 - $62.7 $5.22 Million - $6.95 Million	110,863 Added 256.29%	154,120 $7.26 Million
Q2 2018 Aug 08, 2018	BUY	$26.05 - $52.4 $924,748 - $1.86 Million	35,499 Added 457.58%	43,257 $2.13 Million
Q1 2018 May 07, 2018	BUY	$17.2 - $34.95 $133,437 - $271,142	7,758 New	7,758 $239,000

Others Institutions Holding MRTX

# of Institutions

Shares Held

3.57M

Call Options Held

Put Options Held

36.6K

View Full List

About Mirati Therapeutics, Inc.

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

More about MRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Account